Kine Sciences Begins Phase 1b/2a Study Dosing for CIDP Patients

Kine Sciences, a biopharmaceutical company in the clinical stage, has commenced dosing the first patient in its Phase 1b/2a study of KINE-101 for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Korea. This trial involves patients who have previously undergone at least one frontline treatment regimen. The administration of KINE-101 in this study marks a significant milestone for Kine Sciences as it is the first clinical program for the company. The Chief Executive Officer, Dae Ho Cho, PhD, emphasized the importance of this development and expressed confidence in the potential of KINE-101 to demonstrate strong clinical efficacy, as seen in preclinical studies.

KINE-101 is a novel nanopeptide designed to act as a disease modifier by activating regulatory T cells (Treg). This mechanism sets it apart from other treatments that mainly address symptoms. Kine Sciences believes that KINE-101 could become a more effective treatment option for CIDP, either as a standalone therapy or in combination with existing treatments.

The company's journey with KINE-101 began with a successful Phase 1 study in the United States, which received FDA clearance in September 2021. This Phase 1 study involved 40 healthy participants divided into five cohorts. Four cohorts were administered ascending intravenous doses of KINE-101 (10, 30, 100, and 300 mg), while the fifth cohort received a subcutaneous dose of 96.8 mg. Completed in October 2023, the study demonstrated that KINE-101 has an excellent safety profile, paving the way for the current Phase 1b/2a study.

Kine Sciences is also exploring the potential of KINE-101 for other medical conditions such as Inflammatory Bowel Disease, Rheumatoid Arthritis, and Non-Alcoholic Steatohepatitis. The company's broader pipeline continues to advance with several novel candidates undergoing preclinical studies for various indications.

Founded in 2016, Kine Sciences focuses on developing ultra-small peptides for a variety of immune-mediated diseases using functional immunomics. The company's unique peptides originate from a novel anti-inflammatory cytokine targeting different immune cells. The ultra-small size of these peptides offers several advantages, including a favorable pharmacokinetic vs. pharmacodynamic profile, low immunogenicity, low antigenicity, reduced production costs, and the potential for oral administration.

In summary, the initiation of the Phase 1b/2a study for KINE-101 in CIDP patients marks an important milestone for Kine Sciences. The company is optimistic about the clinical outcomes and the potential of KINE-101 to provide more effective treatment options for CIDP patients. With its unique mechanism of action and promising preclinical results, KINE-101 stands out in the landscape of immune-mediated disease treatments. Kine Sciences continues to advance its pipeline, exploring the use of its innovative peptides in various medical conditions and pushing forward the boundaries of biopharmaceutical development.